Fulcrum Therapeutics (FULC) EBITDA Margin (2020 - 2024)
Fulcrum Therapeutics (FULC) reported EBITDA Margin of 65.61% for Q2 2024, up 316698.0% year-over-year from N/an in Q3 2023, and up 102.04% quarter-over-quarter from 3213.78% in Q4 2023.
Fulcrum Therapeutics (FULC) EBITDA Margin (2020 - 2024) Analysis & Trends
Fulcrum Therapeutics (FULC) has 5 years of EBITDA Margin data on file, last reported at 65.61% in Q2 2024.
- EBITDA Margin for Q2 2024 came in at 65.61%, up 316698.0% year-over-year; the trailing twelve-month figure through Jun 2025 was 94.12% (down 5724.0% YoY), and the FY2024 annual result was 11.82%, up 343466.0% from the prior year.
- EBITDA Margin grew to 65.61% in Q2 2024 per FULC's latest filing, from 3213.78% in the prior quarter.
- Over five years, EBITDA Margin peaked at 65.61% in Q2 2024 and troughed at 9471.19% in Q1 2023.
- A 5-year average of 2041.4% and a median of 1028.79% in 2020 frame the typical range for EBITDA Margin.
- The sharpest annual moves came in 2023 and 2024: EBITDA Margin slumped 844414 bps in 2023, then soared 316698 bps in 2024.
- A 5-year view of EBITDA Margin shows it stood at 420.19% in 2020, then declined by 12 bps to 470.42% in 2021, then plunged by 768 bps to 4083.65% in 2022, then advanced by 21 bps to 3213.78% in 2023, then soared by 102 bps to 65.61% in 2024.
- Business Quant data shows FULC's EBITDA Margin at 65.61% in Q2 2024, 3213.78% in Q4 2023, and 3615.28% in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | -6.43% |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Fulcrum Therapeutics | 267.90 Mn | 267.90 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 65.62% |
| Dec 31, 2023 | -3,213.78% |
| Sep 30, 2023 | -3,615.28% |
| Jun 30, 2023 | -3,101.36% |
| Mar 31, 2023 | -9,471.19% |
| Dec 31, 2022 | -4,083.65% |
| Sep 30, 2022 | -2,058.75% |
| Jun 30, 2022 | -1,809.14% |
| Mar 31, 2022 | -1,027.04% |
| Dec 31, 2021 | -470.42% |
| Sep 30, 2021 | -421.36% |
| Jun 30, 2021 | -448.60% |
| Mar 31, 2021 | -355.00% |
| Dec 31, 2020 | -420.19% |
| Sep 30, 2020 | -1,028.79% |
| Jun 30, 2020 | -777.55% |
| Mar 31, 2020 | -2,467.33% |